BRPI0909227A2 - uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin. - Google Patents

uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin.

Info

Publication number: BRPI0909227A2
Authority: BR; Brazil
Prior art keywords: antibody; adcc; lymphomas; vincristine; hodgkin
Prior art date: 2008-03-25

Application number

BRPI0909227A

Other languages

English (en)

Inventor

Charles Dumontet

Christian Klein

Frank Herting

Pablo Umana

Thomas Friess

Original Assignee

Roche Glycart Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-25

Filing date

2009-03-23

Publication date

2015-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40872445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909227(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-23 Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag

2015-12-01 Publication of BRPI0909227A2 publication Critical patent/BRPI0909227A2/pt

2020-11-24 Publication of BRPI0909227B1 publication Critical patent/BRPI0909227B1/pt

2021-05-25 Publication of BRPI0909227B8 publication Critical patent/BRPI0909227B8/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0909227A 2008-03-25 2009-03-23 uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl) BRPI0909227B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP08005554		2008-03-25
EP08005554.4		2008-03-25
EP08007172.3		2008-04-11
EP08007172		2008-04-11
PCT/EP2009/002111 WO2009118142A1 (en)	2008-03-25	2009-03-23	Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas

Publications (3)

Publication Number	Publication Date
BRPI0909227A2 true BRPI0909227A2 (pt)	2015-12-01
BRPI0909227B1 BRPI0909227B1 (pt)	2020-11-24
BRPI0909227B8 BRPI0909227B8 (pt)	2021-05-25

Family

ID=40872445

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909227A BRPI0909227B8 (pt)	2008-03-25	2009-03-23	uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)

Country Status (31)

Country	Link
US (6)	US20090246197A1 (pt)
EP (1)	EP2268310B1 (pt)
JP (3)	JP5547709B2 (pt)
KR (1)	KR101280716B1 (pt)
CN (2)	CN107198772A (pt)
AR (1)	AR072947A1 (pt)
AU (1)	AU2009228616B2 (pt)
BR (1)	BRPI0909227B8 (pt)
CA (1)	CA2716884C (pt)
CL (1)	CL2009000713A1 (pt)
CR (1)	CR11687A (pt)
CY (1)	CY1117984T1 (pt)
DK (1)	DK2268310T3 (pt)
ES (1)	ES2592312T3 (pt)
HR (1)	HRP20161301T1 (pt)
HU (1)	HUE028828T2 (pt)
IL (1)	IL208018A (pt)
LT (1)	LT2268310T (pt)
MA (1)	MA32140B1 (pt)
MX (1)	MX2010009647A (pt)
MY (1)	MY163544A (pt)
NZ (1)	NZ587284A (pt)
PE (1)	PE20091821A1 (pt)
PL (1)	PL2268310T3 (pt)
PT (1)	PT2268310T (pt)
RS (1)	RS55258B1 (pt)
RU (1)	RU2589704C2 (pt)
SI (1)	SI2268310T1 (pt)
TW (1)	TWI500624B (pt)
WO (1)	WO2009118142A1 (pt)
ZA (1)	ZA201006190B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2961563B2 (ja)	1991-01-29	1999-10-12	株式会社トーキン	パルス発生用磁気ワイヤの製造方法
US9296820B2 (en)	2003-11-05	2016-03-29	Roche Glycart Ag	Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
RU2589704C2 (ru) *	2008-03-25	2016-07-10	Роше Гликарт Аг	Применение антитела к cd20 типа ii, обладающего повышенной антитело-обусловленной клеточнозависимой цитотоксичностью (adcc), в сочетании с циклофосфамидом, винкристином и доксорубицином для лечения неходжкинских лимфом
AR073295A1 (es)	2008-09-16	2010-10-28	Genentech Inc	Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CA3007787C (en)	2010-06-03	2020-03-10	Pharmacyclics Llc	The use of inhibitors of bruton's tyrosine kinase (btk)
WO2012080389A1 (en) *	2010-12-16	2012-06-21	Roche Glycart Ag	Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
MX391121B (es) *	2011-10-19	2025-03-19	Pharmacyclics Llc	Uso de inhibidores de la tirosina cinasa de bruton (btk).
US20130302274A1 (en) *	2011-11-25	2013-11-14	Roche Glycart Ag	Combination therapy
CN104704129A (zh)	2012-07-24	2015-06-10	药品循环公司	与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
AU2014364593A1 (en) *	2013-12-17	2016-07-07	Genentech, Inc.	Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PH12017500442B1 (en)	2014-09-09	2023-05-24	Janssen Biotech Inc	Combination therapies with anti-cd38 antibodies
CN107406506A (zh)	2014-12-04	2017-11-28	詹森生物科技公司	用于治疗急性髓系白血病的抗cd38抗体
JP6961490B2 (ja)	2015-04-08	2021-11-05	ノバルティスアーゲー	Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
EA201792546A1 (ru)	2015-05-20	2018-04-30	Янссен Байотек, Инк.	Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
IL256242B2 (en)	2015-06-22	2024-09-01	Janssen Biotech Inc	Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en)	2015-11-03	2020-09-22	Janssen Biotech, Inc.	Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3004152C (en)	2015-11-03	2024-04-16	Janssen Biotech, Inc.	Subcutaneous formulations of anti-cd38 antibodies and their uses
CN108603037B (zh) *	2015-12-10	2020-11-17	希望之城	细胞穿透花青偶联抗体
US20190233533A1 (en)	2016-06-28	2019-08-01	Umc Utrecht Holding B.V.	Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
BR112019006781A2 (pt)	2016-10-07	2019-07-30	Novartis Ag	receptores de antígeno quiméricos para o tratamento de câncer
WO2018106945A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
MA50514A (fr)	2017-10-31	2020-09-09	Janssen Biotech Inc	Méthodes de traitement du myélome multiple à haut risque
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
EP3883635A1 (en)	2018-11-19	2021-09-29	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
AR122307A1 (es)	2019-10-04	2022-08-31	Chugai Pharmaceutical Co Ltd	Agente de supresión de la proliferación celular de cáncer cd20 positivo tolerante a obinutuzumab, y composición farmacéutica, medicamento, fabricación, procedimiento de supresión de la proliferación celular, procedimiento de tratamiento, anticuerpo anti-cd20 de tipo ii, compuesto, sus combinaciones, y agente potenciador y agente inductor, relacionados con estos
CN115666704B (zh)	2019-12-13	2025-09-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
TW202337494A (zh)	2021-11-16	2023-10-01	美商建南德克公司	用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK1071700T3 (da) *	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
RU2306952C2 (ru) *	2001-01-31	2007-09-27	Байоджен Айдек Инк.	Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
BRPI0315295C1 (pt) *	2002-10-17	2021-05-25	Genmab As	anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
TWI335821B (en) *	2002-12-16	2011-01-11	Genentech Inc	Immunoglobulin variants and uses thereof
US9296820B2 (en) *	2003-11-05	2016-03-29	Roche Glycart Ag	Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
JP2008541758A (ja) *	2005-06-02	2008-11-27	アストラゼネカエービー	Ｃｄ２０に対する抗体およびその使用
AU2006290433B2 (en) *	2005-08-26	2012-06-07	Roche Glycart Ag	Modified antigen binding molecules with altered cell signaling activity
AU2008295140A1 (en) *	2007-09-05	2009-03-12	F. Hoffmann-La Roche Ag	Combination therapy with type I and type II anti-CD20 antibodies
RU2589704C2 (ru) *	2008-03-25	2016-07-10	Роше Гликарт Аг	Применение антитела к cd20 типа ii, обладающего повышенной антитело-обусловленной клеточнозависимой цитотоксичностью (adcc), в сочетании с циклофосфамидом, винкристином и доксорубицином для лечения неходжкинских лимфом

2009
- 2009-03-23 RU RU2010143454/15A patent/RU2589704C2/ru active
- 2009-03-23 TW TW098109412A patent/TWI500624B/zh active
- 2009-03-23 CN CN201611215290.7A patent/CN107198772A/zh active Pending
- 2009-03-23 WO PCT/EP2009/002111 patent/WO2009118142A1/en not_active Ceased
- 2009-03-23 HU HUE09723808A patent/HUE028828T2/en unknown
- 2009-03-23 NZ NZ587284A patent/NZ587284A/en unknown
- 2009-03-23 DK DK09723808.3T patent/DK2268310T3/en active
- 2009-03-23 CN CN2009801101810A patent/CN101983071A/zh active Pending
- 2009-03-23 CA CA2716884A patent/CA2716884C/en active Active
- 2009-03-23 HR HRP20161301TT patent/HRP20161301T1/hr unknown
- 2009-03-23 AU AU2009228616A patent/AU2009228616B2/en active Active
- 2009-03-23 PT PT97238083T patent/PT2268310T/pt unknown
- 2009-03-23 KR KR1020107021332A patent/KR101280716B1/ko active Active
- 2009-03-23 ES ES09723808.3T patent/ES2592312T3/es active Active
- 2009-03-23 SI SI200931530A patent/SI2268310T1/sl unknown
- 2009-03-23 LT LTEP09723808.3T patent/LT2268310T/lt unknown
- 2009-03-23 MX MX2010009647A patent/MX2010009647A/es active IP Right Grant
- 2009-03-23 PL PL09723808T patent/PL2268310T3/pl unknown
- 2009-03-23 JP JP2011501133A patent/JP5547709B2/ja active Active
- 2009-03-23 CL CL2009000713A patent/CL2009000713A1/es unknown
- 2009-03-23 AR ARP090101035A patent/AR072947A1/es unknown
- 2009-03-23 RS RS20160864A patent/RS55258B1/sr unknown
- 2009-03-23 EP EP09723808.3A patent/EP2268310B1/en active Active
- 2009-03-23 MY MYPI2010004461A patent/MY163544A/en unknown
- 2009-03-23 BR BRPI0909227A patent/BRPI0909227B8/pt active IP Right Grant
- 2009-03-23 US US12/408,746 patent/US20090246197A1/en not_active Abandoned
- 2009-03-24 PE PE2009000437A patent/PE20091821A1/es not_active Application Discontinuation
2010
- 2010-05-10 US US12/777,141 patent/US20100310581A1/en not_active Abandoned
- 2010-08-30 ZA ZA2010/06190A patent/ZA201006190B/en unknown
- 2010-09-03 MA MA33145A patent/MA32140B1/fr unknown
- 2010-09-06 IL IL208018A patent/IL208018A/en active IP Right Grant
- 2010-09-23 CR CR11687A patent/CR11687A/es unknown
2011
- 2011-03-07 US US13/042,305 patent/US20110177067A1/en not_active Abandoned
- 2011-10-28 US US13/284,415 patent/US20120301459A1/en not_active Abandoned
2013
- 2013-03-14 US US13/829,409 patent/US20140065134A1/en not_active Abandoned
2014
- 2014-01-24 JP JP2014011332A patent/JP5912142B2/ja active Active
- 2014-06-05 US US14/297,478 patent/US20160000911A1/en not_active Abandoned
2016
- 2016-03-18 JP JP2016055096A patent/JP6154039B2/ja active Active
- 2016-09-07 CY CY20161100889T patent/CY1117984T1/el unknown

Also Published As

Publication number	Publication date
LT2268310T (lt)	2016-09-26
US20110177067A1 (en)	2011-07-21
HUE028828T2 (en)	2017-01-30
US20100310581A1 (en)	2010-12-09
ZA201006190B (en)	2018-11-28
JP6154039B2 (ja)	2017-06-28
KR101280716B1 (ko)	2013-07-01
CA2716884C (en)	2017-10-03
US20140065134A1 (en)	2014-03-06
CN107198772A (zh)	2017-09-26
PE20091821A1 (es)	2009-11-25
CR11687A (es)	2011-01-10
BRPI0909227B8 (pt)	2021-05-25
NZ587284A (en)	2012-05-25
JP2016121183A (ja)	2016-07-07
SI2268310T1 (sl)	2016-11-30
JP5547709B2 (ja)	2014-07-16
BRPI0909227B1 (pt)	2020-11-24
EP2268310A1 (en)	2011-01-05
DK2268310T3 (en)	2016-08-15
MY163544A (en)	2017-09-29
WO2009118142A1 (en)	2009-10-01
RS55258B1 (sr)	2017-02-28
RU2010143454A (ru)	2012-05-10
KR20100121525A (ko)	2010-11-17
RU2589704C2 (ru)	2016-07-10
JP5912142B2 (ja)	2016-04-27
IL208018A (en)	2017-12-31
TWI500624B (zh)	2015-09-21
JP2011515428A (ja)	2011-05-19
PL2268310T3 (pl)	2017-08-31
CA2716884A1 (en)	2009-10-01
TW200951141A (en)	2009-12-16
HRP20161301T1 (hr)	2016-11-18
EP2268310B1 (en)	2016-07-20
AR072947A1 (es)	2010-10-06
MX2010009647A (es)	2010-09-28
MA32140B1 (fr)	2011-03-01
CL2009000713A1 (es)	2010-04-09
US20090246197A1 (en)	2009-10-01
IL208018A0 (en)	2010-12-30
AU2009228616A1 (en)	2009-10-01
ES2592312T3 (es)	2016-11-29
CN101983071A (zh)	2011-03-02
US20160000911A1 (en)	2016-01-07
AU2009228616B2 (en)	2014-07-24
CY1117984T1 (el)	2017-05-17
JP2014101370A (ja)	2014-06-05
US20120301459A1 (en)	2012-11-29
PT2268310T (pt)	2016-08-23

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-06-18	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2020-04-07	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-09-29	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-11-24	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
BRPI0909227A2 (pt)	2015-12-01	uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin.
WO2009086471A3 (en)	2009-09-11	Synergistic antiparasitic compositions and screening methods
BRPI0722259A2 (pt)	2014-04-08	Método para produção de um vestuário absorvente, e vestuário absorvente produzido de acordo com o método
WO2008003007A3 (en)	2008-05-22	Compositions and methods for treating parasitic infections
BRPI0814420A2 (pt)	2015-11-17	composição, e, uso de álcool alcoxilado.
MX373050B (es)	2020-05-21	Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojos.
CR11274A (es)	2010-05-31	Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
BRPI0813680A2 (pt)	2015-01-06	AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
BRPI0819047A2 (pt)	2015-05-05	"composição, seu processo de preparação e seus usos"
ECSP109940A (es)	2010-03-31	Anticuerpos anti-cd79b e inmunoconjugados humanizados y métodos de uso
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0719345A2 (pt)	2014-03-18	Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
BRPI0808098A2 (pt)	2014-06-17	4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BRPI0718688A2 (pt)	2013-12-24	Composições de baixa irritação e métodos para preparar as mesmas.
BRPI0921249A2 (pt)	2018-10-23	uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.
BRPI0908503A2 (pt)	2015-09-29	partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI1006974A2 (pt)	2017-05-30	"uso de absorvedores de uv, e, composição cosmética."
BRPI0911594A2 (pt)	2017-10-10	di-hidropirazolonas substistuídas, seu processo de preparação e seu uso, bem como medicamentos
BRPI0814692A2 (pt)	2015-01-20	Mistura sinergística, uso da mistura sinergística, material orgânico inanimado, composição de combustível, concentrado de aditivo, e, composição lubrificante
BRPI0912292A2 (pt)	2015-10-20	composições e métodos para o uso de células no tratamento do tecido cardíaco.
BRPI0808172A2 (pt)	2014-11-04	Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
BRPI0814931A2 (pt)	2015-02-03	Composto com atividade contra hcv, sua composição e seu uso
BRPI0910212A2 (pt)	2015-09-29	partículas compósitas e composição cosmética.
BRPI0815768A2 (pt)	2014-09-30	Uso de absorventes de uv, e, composição cosmética.
BRPI0907053A2 (pt)	2015-07-07	Poliisobutenoamina, composição combustível, e, uso de poliisobutenoaminas